SEC Form 4 · accession 0001209191-17-022141
Cascadian Therapeutics, Inc. · CASC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Dunseth Myers
Officer — President and CEO · Director
Period of report
Mar 20, 2017
Accepted (ET)
Mar 21, 2017 · 8:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001412067
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2017 | P | 1,000 | $3.9271 | A | 39,416 | D |
Table II — derivative securities
No Table II lines on this filing.